Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?

Group 1 - Shares of Adaptive Biotechnologies (ADPT) have increased by 5.1% over the past four weeks, closing at $8.81, with a mean price target of $11.14 indicating a potential upside of 26.5% [1] - The average price targets from analysts range from a low of $9 to a high of $13, with a standard deviation of $1.57, suggesting a variability in estimates; the lowest estimate indicates a 2.2% increase, while the highest points to a 47.6% upside [2] - Analysts show strong agreement in revising earnings estimates higher for ADPT, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 5.5% over the past month [4][12] Group 2 - ADPT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside in the near term [13] - The consensus price target, while not entirely reliable, suggests a positive direction for ADPT's price movement, supported by the recent upward revisions in earnings estimates [11][13]